Salvage Therapy in Autoimmune Hepatitis
C
Craig Lammert, MD
Primary Investigator
Overview
The purpose of the study is assess treatment outcomes in people who are taking rituximab as treatment for autoimmune hepatitis (AIH). The treatment itself is not part of the study.
Eligibility
You may be eligible for this study if you meet the following criteria:
-
Conditions:
Autoimmune Hepatitis
-
Age: Between 18 Years - 100 Years
-
Gender: All
Inclusion Criteria
Initiation of rituximab as treatment for AIH
Updated on
08 May 2024.
Study ID: 1903230072
Please visit our main page to search for other studies you may be interested in.
If you need help finding a study or have any questions, please contact us at inhealth@iu.edu
